MicroCavitics

Protect Hearts Everywhere

MicroCavitics is an Australian MedTech startup developing MUSIC (Trade Mark application underway) — a patented microbubble-ultrasound therapy that restores microvascular flow after heart attacks. Despite rapid reperfusion, up to 50% of patients suffer microvascular obstruction with no effective treatment. Our portable device combines targeted microbubble infusion with low-intensity ultrasound to reopen blocked microvessels, improving myocardial salvage (79% vs 48% in pilot data). Backed by major research grants and leading institutes, MicroCavitics targets a >$10B global market, aiming for first-in-human trials 2026/27 and to make microvascular repair as routine as reperfusion.

Achievements:

-Human Proof-Of-Concept Trial completed; -Developed and tested prototype system to TRL4; -Successfully secured multiple government grants ($~2.5M)

Team: Kazuaki Negishi, MD, PhD Founder and CEO, Cardiologist and Prof/Chair Cardiovascular Research at UNSW Western Sydney; Tomoko Negishi, MD, Co-Founder (Senior Cardiologist & Trial lead); Hiroshi Nagai, PhD (Engineer); Yasuhiro Nakajima (Commercial & Sales Lead)

Kazuaki Negishi, MD, PhD Founder and CEO